Search research articles
Contact Us
Filters
Showing results (91-100 of 188) with videos related to
Page
of 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Omid Hamid, Luciana Molinero, Christopher R Bolen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2021
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
Michele Maio, Matteo S Carlino, Anthony M Joshua, et al.
Nature Medicine
|
July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Georgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Cancer Immunology, Immunotherapy : CII
|
February 6, 2019
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
Sandra P D'Angelo, Matthias Hunger, Andrew S Brohl, et al.
Nature Medicine
|
June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney, Igor Puzanov, Frances Collichio, et al.
Cell Reports. Medicine
|
April 16, 2025
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific
Joseph J Sacco, Peter Kirk, Emma Leach, et al.
The Oncologist
|
September 29, 2025
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients
Tristan L Lim, Kamaneh Montazeri, Eric Wehrenberg-Klee, et al.
Melanoma Research
|
October 28, 2017
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E
Sigrun Hallmeyer, Rene Gonzalez, David H Lawson, et al.
Page
of 19
Search research articles
Search
Showing results (91-100 of 188) with videos related to
Sort By:
Page
of 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab
Omid Hamid, Luciana Molinero, Christopher R Bolen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2021
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
Michele Maio, Matteo S Carlino, Anthony M Joshua, et al.
Nature Medicine
|
July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Georgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Cancer Immunology, Immunotherapy : CII
|
February 6, 2019
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
Sandra P D'Angelo, Matthias Hunger, Andrew S Brohl, et al.
Nature Medicine
|
June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney, Igor Puzanov, Frances Collichio, et al.
Cell Reports. Medicine
|
April 16, 2025
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific
Joseph J Sacco, Peter Kirk, Emma Leach, et al.
The Oncologist
|
September 29, 2025
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients
Tristan L Lim, Kamaneh Montazeri, Eric Wehrenberg-Klee, et al.
Melanoma Research
|
October 28, 2017
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E
Sigrun Hallmeyer, Rene Gonzalez, David H Lawson, et al.
Page
of 19